Karo Bio's Prescription: Cheaper Drug Approval

摘要

Karo Bio, a tiny Swedish biotech company with no products on the market, has a big problem. Its experimental cholesterol-lowering pill is a potential blockbuster. But only if it can raise the $500 million needed to bankroll up to five years of large-scale testing normally required for widely used drugs that combat disease in unfamiliar ways.rnKaro's prescription for its predicament is as novel as its compound: enlist one of the world's premier cardiologists to help convince the Food & Drug Administration that such expansive-and expensive-testing is not needed.